Sigrima™

Sigrima™ 420mg/14mlis an advanced oncology medication containing Pertuzumab, a recombinant humanized monoclonal antibody designed for targeted cancer therapy. It specifically targets and binds to the human epidermal growth factor receptor 2 (HER2) protein overexpressed on the surface of certain malignant cells. By blocking these receptors, it interrupts growth signals to inhibit cell division and slow tumor progression.Manufactured by Zydus, Sigrima™ is indicated for the treatment of HER2-positive early and metastatic breast cancers. It is typically administered as an intravenous infusion by medical professionals in combination with trastuzumab and chemotherapy regimens.Dacoplice® 30 mg contains Dacomitinib, an advanced antineoplastic medication categorized as a tyrosine kinase inhibitor (TKI). Developed by Pfizer, this targeted therapy is primarily indicated as a first-line treatment for adults diagnosed with metastatic non-small cell lung cancer (NSCLC) harboring specific epidermal growth factor receptor (EGFR) mutations. By precisely binding to and blocking the abnormal proteins driving malignant cellular division, Dacoplice® effectively slows or halts the proliferation and spread of tumor cells. Administered orally under strict oncological supervision, it plays a vital role in modern precision oncology regimens to manage advanced disease progression.